The FDA granted accelerated approval to telisotuzumab vedotin (Emrelis) for the treatment of adults with previously treated, ...

AbbVie's Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who ...

The U.S. Food and Drug Administration has approved AbbVie's drug to treat adults with a type of lung cancer who have received ...

Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L ...

Biotech company AbbVie (ABBV) said on Wednesday that the U.S. Food and Drug Administration has approved Emrelis medicine for ...

Diagnosed with stage 4 lung cancer in 2020, Sanjay Dutt turned to chemotherapy, exercise, and family support in his fight ...

Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize care and address ...

AbbVie has claimed its first regulatory approval, from the FDA, for its C-met-targeting antibody-drug conjugate (ADC) Emrelis ...

After flexing its antibody-drug conjugate bona fides at last year’s American Society of Clinical Oncology (ASCO) conference, ...

The U.S. Food and Drug Administration (FDA) granted accelerated approval to AbbVie Inc.’s (NYSE:ABBV) Emrelis (telisotuzumab vedotin-tllv) for adult patients with locally advanced or metastatic, ...

AbbVie has received accelerated approval from the U.S. Food and Drug Administration (FDA) for EMRELIS (telisotuzumab ...

Caris remains committed to advancing cancer diagnostics and treatment through innovative technologies and rigorous scientific ...